Drug-induced fatty liver disease: An overview of pathogenesis and management

Annals of Hepatology

Volumn 14, Issue 6, 2015, Pages 789-806

  Satapathy, Sanjaya K ^a   Kuwajima, Vanessa ^b   Nadelson, Jeffrey ^b   Atiq, Omair ^c   Sanyal, Arun J ^d  

^a METHODIST UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Cirrhosis; Drug induced NAFLD; Drug induced NASH; Fatty liver; Insulin resistance; NASH

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; ALPHA TOCOPHEROL; AMIODARONE; CARBAMAZEPINE; DIDANOSINE; FLUOROURACIL; FLUOXETINE; GENTAMICIN; GLUCOCORTICOID; HEXESTROL BIS(2 DIETHYLAMINOETHYL) ETHER; IBUPROFEN; INTERLEUKIN 6; IRINOTECAN; LEPTIN; METHOTREXATE; OBETICHOLIC ACID; PERHEXILINE; PERHEXILINE MALEATE; PROTEINASE INHIBITOR; RESISTIN; RETINOL; SILYMARIN; STAVUDINE; TAMOXIFEN; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID; ZIDOVUDINE; ADENOSINE TRIPHOSPHATE; FATTY ACID;

ADVERSE OUTCOME; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; FATTY ACID METABOLISM; GENETIC PREDISPOSITION; HUMAN; INSULIN RESISTANCE; LIPIDOSIS; LIPOPROTEIN METABOLISM; LIVER BIOPSY; LIVER CELL; LIVER MITOCHONDRION; MACROVESICULAR STEATOSIS; MICROSOME; MICROVESICULAR STEATOSIS; NONALCOHOLIC FATTY LIVER; OBESITY; OUTCOME ASSESSMENT; PATHOGENESIS; PEROXISOME; PROTEIN FUNCTION; REVIEW; STEATOSIS; ANIMAL; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENERGY METABOLISM; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR; TREATMENT OUTCOME;

ADENOSINE TRIPHOSPHATE; ANIMALS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENERGY METABOLISM; FATTY ACIDS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER; MITOCHONDRIA, LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84943174744     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.5604/16652681.1171749     Document Type: Review

References (168)

1. Younossi ZM, Stepanova M, Afendy M, Younossi ZM, Stepanova M, Afendy M, Fang Y, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-30 e1; quiz e60.
2. Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 2010; 11: 430-45.
3. Abenavoli L, Masarone M, Peta V, Milic N, Kobyliak N, Rouabhia S, Persico M, et al. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J Gastroenterol 2014; 20: 15233-40.
4. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012; 32: 3-13.
5. Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, Neuschwander-Tetri BA, et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009; 49: 809-20.
6. Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002; 22: 185-94.
7. Stravitz RT, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis 2003; 7: 435-51.
8. Fromenty B, Pessayre D. Inhibition of mitochondrial betaoxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995; 67: 101-54.
9. Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol 2009; 62: 481-92.
10. Robison RL, Visscher GE, Roberts SA, Engstrom RG, Hartman HA, Ballard FH. Generalized phospholipidosis induced by an amphiphilic cationic psychotropic drug. Toxicol Pathol 1985; 13: 335-48.
11. Anderson N, Borlak J. Drug-induced phospholipidosis. FEBS Lett 2006; 580: 5533-40.
12. Kodavanti UP, Mehendale HM. Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol Rev 1990; 42: 327-54.
13. Pessayre D, Berson A, Fromenty B, Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 2001; 21: 57-69.
14. Vajro P, Fontanella A, Perna C, Orso G, Tedesco M, De Vincenzo A. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994; 125: 239-41.
15. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006; 49: 755-65.
16. Chan DC, Watts GF, Gan S, Wong AT, Ooi EM, Barrett PH. Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very-low-density lipoprotein-apolipoprotein B-100 in obesity. Arterioscler Thromb Vasc Biol 2010; 30: 1043-50.
17. Gerber N, Dickinson RG, Harland RC, Lynn RK, Houghton LD, Antonias JI, Schimschock JC. Reye-like syndrome associated with valproic acid therapy. J Pediatr 1979; 95: 142-4.
18. Zimmerman HJ, Ishak KG. Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology 1982; 2: 591-7.
19. Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol 2011; 54: 773-94.
20. Serviddio G, Bellanti F, Vendemiale G, Altomare E. Mitochondrial dysfunction in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011; 5: 233-44.
21. Fromenty B, Fisch C, Berson A, Letteron P, Larrey D, Pessayre D. Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J Pharmacol Exp Ther 1990; 255: 1377-84.
22. Deschamps D, DeBeco V, Fisch C, Fromenty B, Guillouzo A, Pessayre D. Inhibition by perhexiline of oxidative phosphorylation and the beta-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology 1994; 19: 948-61.
23. Larosche I, Letteron P, Fromenty B, Vadrot N, Abbey-Toby A, Feldmann G, Pessayre D, et al. Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. J Pharmacol Exp Ther 2007; 321: 526-35.
24. Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 2008; 22: 335-53.
25. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006; 6: 1-28.
26. Lewis W, Levine ES, Griniuviene B, Tankersley KO, Colacino JM, Sommadossi JP, Watanabe KA, et al. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci U S A 1996; 93: 3592-7.
27. Walker UA, Venhoff N. Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity. Antivir Ther 2005; 10(Suppl. 2): M117-M123.
28. Cornejo-Juarez P, Sierra-Madero J, Volkow-Fernandez P. Metabolic acidosis and hepatic steatosis in two HIV-infected patients on stavudine (d4T) treatment. Arch Med Res 2003; 34: 64-9.
29. Walker UA, Bauerle J, Laguno M, Murillas J, Mauss S, Schmutz G, Setzer B, et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004; 39: 311-7.
30. Wu Y, Li N, Zhang T, Wu H, Huang C, Chen D. Mitochondrial DNA base excision repair and mitochondrial DNA mutation in human hepatic HuH-7 cells exposed to stavudine. Mutat Res 2009; 664: 28-38.
31. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7: 195-203.
32. Letteron P, Sutton A, Mansouri A, Fromenty B, Pessayre D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 2003; 38: 133-40.
33. Blas-Garcia A, Apostolova N, Ballesteros D, Monleon D, Morales JM, Rocha M, Victor VM, et al. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 2010; 52: 115-25.
34. Thomson DM, Winder WW. AMP-activated protein kinase control of fat metabolism in skeletal muscle. Acta Physiol (Oxf) 2009; 196: 147-54.
35. Jia Y, Viswakarma N, Fu T, Yu S, Rao MS, Borensztajn J, Reddy JK. Conditional ablation of mediator subunit MED1 (MED1/PPARBP) gene in mouse liver attenuates glucocorticoid receptor agonist dexamethasone-induced hepatic steatosis. Gene Expr 2009; 14: 291-306.
36. Schadinger SE, Bucher NL, Schreiber BM, Farmer SR. PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab 2005; 288: E1195-E1205.
37. Moya M, Gomez-Lechon MJ, Castell JV, Jover R. Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. Chem Biol Interact 2010; 184: 376-87.
38. Harmsen S, Meijerman I, Beijnen JH, Schellens JH. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol 2009; 64: 35-43.
39. Bedoucha M, Atzpodien E, Boelsterli UA. Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 2001; 35: 17-23.
40. Halliwell WH. Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol 1997; 25: 53-60.
41. Reasor MJ, Hastings KL, Ulrich RG. Drug-induced phospholipidosis: issues and future directions. Expert Opin Drug Saf 2006; 5: 567-83.
42. Sawada H, Takami K, Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci 2005; 83: 282-92.
43. Pessayre D, Mansouri A, Berson A, Fromenty B. Mitochondrial involvement in drug-induced liver injury. Handb Exp Pharmacol 2010; 196: 311-65.
44. Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogel S, Dargel R, et al. The lipid peroxidation end product 4-hydroxy-2, 3-nonenal up-regulates transforming growth factor beta1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J 1997; 11: 851-7.
45. Mitchell C, Robin MA, Mayeuf A, Mahrouf-Yorgov M, Mansouri A, Hamard M, Couton D, et al. Protection against hepatocyte mitochondrial dysfunction delays fibrosis progression in mice. Am J Pathol 2009; 175: 1929-37.
46. Nieto N, Friedman SL, Cederbaum AI. Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species. Hepatology 2002; 35: 62-73.
47. Comporti M. Three models of free radical-induced cell injury. Chem Biol Interact 1989; 72: 1-56.
48. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991; 11: 81-128.
49. Hruszkewycz AM. Evidence for mitochondrial DNA damage by lipid peroxidation. Biochem Biophys Res Commun 1988; 153: 191-7.
50. Black D, Lyman S, Qian T, Lemasters JJ, Rippe RA, Nitta T, Kim JS, et al. Transforming growth factor beta mediates hepatocyte apoptosis through Smad3 generation of reactive oxygen species. Biochimie 2007; 89: 1464-73.
51. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11: 183-90.
52. Abenavoli L, Peta V. Role of adipokines and cytokines in non-alcoholic fatty liver disease. Rev Recent Clin Trials 2014; 9: 134-40.
53. Wei Y, Clark SE, Morris EM, Thyfault JP, Uptergrove GM, Whaley-Connell AT, Ferrario CM, et al. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol 2008; 49: 417-28.
54. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008; 103: 1372-9.
55. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 1999; 130: 671-80.
56. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science 1996; 274: 1185-8.
57. Marra F. Leptin and liver fibrosis: a matter of fat. Gastroenterology 2002; 122: 1529-32.
58. Ikejima K, Honda H, Yoshikawa M, Hirose M, Kitamura T, Takei Y, Sato N. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 2001; 34: 288-97.
59. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007; 132: 2169-80.
60. Nieto N. Oxidative-stress and IL-6 mediate the fibrogenic effects of [corrected] Kupffer cells on stellate cells. Hepatology 2006; 44: 1487-501.
61. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-9.
62. Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 2005; 152: 113-8.
63. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100.
64. Diehl AM. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol 2002; 282: G1-G5.
65. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96: 1723-32.
66. Lutchman G, Promrat K, Kleiner DE, Heller T, Ghany MG, Yanovski JA, Liang TJ, et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 2006; 4: 1048-52.
67. Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 2009; 50: 1087-93.
68. Van Wagner LB, Koppe SW, Brunt EM, Gottstein J, Gardikiotes K, Green RM, Rinella ME. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2011; 10: 277-86.
69. Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 1946-52.
70. Serviddio G, Sastre J, Bellanti F, Vina J, Vendemiale G, Altomare E. Mitochondrial involvement in non-alcoholic steatohepatitis. Mol Aspects Med 2008; 29: 22-35.
71. Pessayre D, Mansouri A, Haouzi D, Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 1999; 15: 367-73.
72. Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, Parker WD, Jr. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 430-4.
73. Haque M, Sanyal AJ. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2002; 16: 709-31.
74. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735-44.
75. Pessayre DFG, Haouzi D, Fau D, Moreau A, Neuman M. Hepatocyte apoptosis triggered by natural substances (cytokines, other endogenous substances and foreign toxins). Handbook of Experimental Pharmacology 2000; 142: 59-108.
76. Syn WK, Choi SS, Diehl AM. Apoptosis and cytokines in nonalcoholic steatohepatitis. Clin Liver Dis 2009; 13: 565-80.
77. Weltman MD, Farrell GC, Hall P, Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-33.
78. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111: 1645-53.
79. Leclercq IA, Field J, Enriquez A, Farrell GC, Robertson GR. Constitutive and inducible expression of hepatic CYP2E1 in leptin-deficient ob/ob mice. Biochem Biophys Res Commun 2000; 268: 337-44.
80. Schattenberg JM, Wang Y, Singh R, Schattenberg JM, Wang Y, Singh R, Rigoli RM, Czaja MJ. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem 2005; 280: 9887-94.
81. Ekstrom G, Ingelman-Sundberg M. Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1). Biochem Pharmacol 1989; 38: 1313-9.
82. Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 1997; 77: 517-44.
83. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 1999; 103: 1489-98.
84. Bass NM. Three for the price of one knockout-a mouse model of a congenital peroxisomal disorder, steatohepatitis, and hepatocarcinogenesis. Hepatology 1999; 29: 606-8.
85. Reddy JK. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2001; 281: G1333-G1339.
86. Rao MS, Reddy JK. Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis 2001; 21: 43-55.
87. Namikawa C, Shu-Ping Z, Vyselaar JR, Nozaki Y, Nemoto Y, Ono M, Akisawa N, et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol 2004; 40: 781-6.
88. Karpe F, Lundahl B, Ehrenborg E, Eriksson P, Hamsten A. A common functional polymorphism in the promoter region of the microsomal triglyceride transfer protein gene influences plasma LDL levels. Arterioscler Thromb Vasc Biol 1998; 18: 756-61.
89. van't Hooft FM, Lundahl B, Ragogna F, Karpe F, Olivecrona G, Hamsten A. Functional characterization of 4 polymorphisms in promoter region of hepatic lipase gene. Arterioscler Thromb Vasc Biol 2000; 20: 1335-9.
90. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-5.
91. Yuan X, Waterworth D, Perry JR, Lim N, Song K, Chambers JC, Zhang W, et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 2008; 83: 520-8.
92. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, Nobili V, et al. Homozygosity for the patatinlike phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1209-17.
93. Romeo S, Sentinelli F, Cambuli VM, Incani M, Congiu T, Matta V, Pilia S, et al. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol 2010; 53: 335-8.
94. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-94.
95. Kumari M, Schoiswohl G, Chitraju C, Paar M, Cornaciu I, Rangrez AY, Wongsiriroj N, et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab 2012; 15: 691-702.
96. Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol 2008; 14: 6774-85.
97. Grieco A, Forgione A, Miele L, Vero V, Greco AV, Gasbarrini A, Gasbarrini G. Fatty liver and drugs. Eur Rev Med Pharmacol Sci 2005; 9: 261-3.
98. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010; 103: 71-83.
99. Musso G, Gambino R, Cassader M, Pagano G. Metaanalysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-49.
100. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44: 27-33.
101. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54.
102. de Ledinghen V, Vergniol J. Transient elastography (FibroScan). Gastroenterol Clin Biol 2008; 32: 58-67.
103. de Ledinghen V, Vergniol J. Transient elastography for the diagnosis of liver fibrosis. Expert Rev Med Devices 2010; 7: 811-23.
104. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, Kato T, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007; 102: 2708-15.
105. Jones DB MF, Hoofnagle JH, Baranski B. Reye's syndromelike illness in a patient receiving amiodarone. Am J Gastroenterol 1988; 83: 967-69.
106. Beaugrand M, Chousterman M, Callard P, Camilleri JP, Petite J, Ferrier JP. Hepatitis due to perhexiline maleate. Development of cirrhosis after interruption of the drug. Report of two cases (author's transl). Gastroenterol Clin Biol 1977; 1: 745-50.
107. Poucell S, Ireton J, Valencia-Mayoral P, Downar E, Larratt L, Patterson J, Blendis L, et al. Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. Gastroenterology 1984; 86: 926-36.
108. Sopher SM, Camm AJ. Adverse effects of amiodarone at low dose: plus ca change. J Am Coll Cardiol 1997; 30: 799-801.
109. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21: 27-41.
110. Simon JB, Manley PN, Brien JF, Armstrong PW. Amiodarone hepatotoxicity simulating alcoholic liver disease. N Engl J Med 1984; 311: 167-72.
111. Le Gall JY, Guillouzo A, Glaise D, Deugnier Y, Messner M, Bourel M. Perhexiline maleate toxicity on human liver cell lines. Gut 1980; 21: 977-84.
112. Pessayre D, Bichara M, Degott C, Potet F, Benhamou JP, Feldmann G. Perhexiline maleate-induced cirrhosis. Gastroenterology 1979; 76: 170-7.
113. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 1984; 25: 1057-64.
114. Kubo M, Hostetler KY. Metabolic basis of diethylaminoethoxyhexestrol-induced phospholipid fatty liver. Am J Physiol 1987; 252: E375-E379.
115. Berson A, De Beco V, Letteron P, Robin MA, Moreau C, El Kahwaji J, Verthier N, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998; 114: 764-74.
116. Akhondi-Meybodi M, Mortazavy-Zadah MR, Hashemian Z, Moaiedi M. Incidence and risk factors for non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer. Arab J Gastroenterol 2011; 12: 34-6.
117. Ogawa Y, Murata Y, Nishioka A, Inomata T, Yoshida S. Tamoxifen-induced fatty liver in patients with breast cancer. Lancet 1998; 351: 725.
118. Van Hoof M, Rahier J, Horsmans Y. Tamoxifen-induced steatohepatitis. Ann Intern Med 1996; 124: 855-6.
119. Pratt DS, Knox TA, Erban J. Tamoxifen-induced steatohepatitis. Ann Intern Med 1995; 123: 236.
120. Kotiloglu G, Aki ZS, Ozyilkan O, Kutlay L. Tamoxifen-induced cirrhotic process. Breast J 2001; 7: 442-3.
121. Oien KA, Moffat D, Curry GW, Dickson J, Habeshaw T, Mills PR, MacSween RN. Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 1999; 353: 36-7.
122. Grimbert S, Fisch C, Deschamps D, Berson A, Fromenty B, Feldmann G, Pessayre D. Effects of female sex hormones on mitochondria: possible role in acute fatty liver of pregnancy. Am J Physiol 1995; 268: G107-G15.
123. Grimbert S, Fromenty B, Fisch C, Letteron P, Berson A, Durand-Schneider AM, Feldmann G, et al. Decreased mitochondrial oxidation of fatty acids in pregnant mice: possible relevance to development of acute fatty liver of pregnancy. Hepatology 1993; 17: 628-37.
124. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, DeMets DL. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990; 82: 1327-32.
125. Cardoso CM, Custodio JB, Almeida LM, Moreno AJ. Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency. Toxicol Appl Pharmacol 2001; 176: 145-52.
126. Matsumura M, Tashiro K, Miura A, Tajima T, Kinoshita I, Kojima E, Yoshizawa A. A case of non-alcoholic fatty liver disease (NAFLD) aggravated after treatment with raloxifene. Nihon Shokakibyo Gakkai Zasshi 2011; 108: 2036-41.
127. Martins-Maciel ER, Campos LB, Salgueiro-Pagadigorria CL, Bracht A, Ishii-Iwamoto EL. Raloxifene affects fatty acid oxidation in livers from ovariectomized rats by acting as a pro-oxidant agent. Toxicol Lett 2013; 217: 82-9.
128. Itoh S, Igarashi M, Tsukada Y, Ichinoe A. Nonalcoholic fatty liver with alcoholic hyalin after long-term glucocorticoid therapy. Acta Hepatogastroenterol (Stuttg) 1977; 24: 415-8.
129. Letteron P, Brahimi-Bourouina N, Robin MA, Moreau A, Feldmann G, Pessayre D. Glucocorticoids inhibit mitochondrial matrix acyl-CoA dehydrogenases and fatty acid beta-oxidation. Am J Physiol 1997; 272: G1141-G1150.
130. Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001; 56: 172-7.
131. Pylvanen V, Knip M, Pakarinen AJ, Turkka J, Kotila M, Rattya J, Myllyla VV, et al. Fasting serum insulin and lipid levels in men with epilepsy. Neurology 2003; 60: 571-4.
132. Luef G, Rauchenzauner M, Waldmann M, Sturm W, Sandhofer A, Seppi K, Trinka E, et al. Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res 2009; 86: 42-7.
133. Higuchi S, Yano A, Takai S, Tsuneyama K, Fukami T, Nakajima M, Yokoi T. Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury. Toxicol Sci 2012; 130: 4-16.
134. Haukeland JW, Jahnsen J, Raknerud N. Carbamazepineinduced hepatitis. Tidsskr Nor Laegeforen 2000; 120: 2875-7.
135. Grieco A, Alfei B, Di Rocco P, Miele L, Biolcati G, Griso D, Vecchio FM, et al. Non-alcoholic steatohepatitis induced by carbamazepine and variegate porphyria. Eur J Gastroenterol Hepatol 2001; 13: 973-5.
136. Langman G, Hall PM, Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 2001; 16: 1395-401.
137. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200: 845-53.
138. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-72.
139. Larrain S, Rinella ME. A myriad of pathways to NASH. Clin Liver Dis 2012; 16: 525-48.
140. Chariot P, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot MC, Chazaud B, Lombes A, Schaeffer A, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999; 30: 156-60.
141. Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000; 133: 192-6.
142. Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS 1999; 13: 2311-2.
143. Igoudjil A, Massart J, Begriche K, Descatoire V, Robin MA, Fromenty B. High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes. Toxicol In Vitro 2008; 22: 887-98.
144. Chen CH, Vazquez-Padua M, Cheng YC. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991; 39: 625-8.
145. Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, Chmiel JS, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005; 19: 1375-83.
146. Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, Ligabue G, Fiocchi F, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008; 47: 250-7.
147. Crum-Cianflone N, Dilay A, Collins G, Asher D, Campin R, Medina S, Goodman Z, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009; 50: 464-73.
148. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
149. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004; 350: 1220-34.
150. Walli R, Herfort O, Michl GM, Demant T, Jager H, Dieterle C, Bogner JR, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12: F167-F173.
151. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-609.
152. Ogawa Y, Murata Y, Saibara T, Nishioka A, Kariya S, Yoshida S. Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate. Oncol Rep 2003; 10: 1473-8.
153. Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol 2012; 57: 1097-109.
154. Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 2001; 15: 465-89.
155. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385: 956-65.
156. Chen C, Krausz KW, Shah YM, Idle JR, Gonzalez FJ. Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminopheninduced hepatotoxicity. Chem Res Toxicol 2009; 22: 699-707.
157. Burcham PC, Harman AW. Acetaminophen toxicity results in site-specific mitochondrial damage in isolated mouse hepatocytes. J Biol Chem 1991; 266: 5049-54.
158. Freneaux E, Fromenty B, Berson A, Labbe G, Degott C, Letteron P, Larrey D, et al. Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial beta-oxidation of fatty acids. J Pharmacol Exp Ther 1990; 255: 529-35.
159. Moreno-Sanchez R, Bravo C, Vasquez C, Ayala G, Silveira LH, Martinez-Lavin M. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs: study in mitochondria, submitochondrial particles, cells, and whole heart. Biochem Pharmacol 1999; 57: 743-52.
160. Boelsterli UA. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 2003; 192: 307-22.
161. Trost LC, Lemasters JJ. Role of the mitochondrial permeability transition in salicylate toxicity to cultured rat hepatocytes: implications for the pathogenesis of Reye's syndrome. Toxicol Appl Pharmacol 1997; 147: 431-41.
162. Deschamps D, Fisch C, Fromenty B, Berson A, Degott C, Pessayre D. Inhibition by salicylic acid of the activation and thus oxidation of long chain fatty acids. Possible role in the development of Reye's syndrome. J Pharmacol Exp Ther 1991; 259: 894-904.
163. Spaniol M, Bracher R, Ha HR, Follath F, Krähenbühl S. Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. J Hepatol 2001; 35: 628-36.
164. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22: 685-708.
165. Silva MF, Aires CC, Luis PB, Ruiter JP, Ijlst L, Duran M, Wanders RJ, et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 2008; 31: 205-16.
166. Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP, Nishimura Y, Crowe RA, et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1998; 1366: 177-96.
167. Yamamoto N, Oliveira MB, Campello Ade P, Lopes LC, Klüppel ML. Methotrexate: studies on the cellular metabolism. I. Effect on mitochondrial oxygen uptake and oxidative phosphorylation. Cell Biochem Funct 1988; 6: 61-6.
168. Cai Z, Yang J, Shu X, Xiong X. Chemotherapy-associated hepatotoxicity in colorectal cancer. J Buon 2014; 19: 350-6.